RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention

RAK Medical and Health Sciences University

Status: Enrolling

Conditions: Deprescribing; Inappropriate Use; Proton Pump Inhibitors

Treatments: Other: Control (Standard treatment); Other: Pharmacist-Led Educational Intervention

Study type: Interventional

Funder types: Other

Identifiers

NCT06858384

RAKMHSU/RES/2024-25/001

Details and patient eligibility

About

The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI prescriptions in Ras Al Khaimah.

The main questions it aims to answer are:

• Can a pharmacist-led education program reduce unnecessary PPI use?
• Does the intervention improve patients' quality of life and reduce healthcare costs? Researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces PPI use and improves patient outcomes.

Participants will:

• Receive educational materials from pharmacists, including a patient educational brochure, PPI patient decision aid, PPI deprescribing pamphlet, and PPI patient action plan.
• Physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, PPI evidence-based deprescribing guideline, PPI deprescribing algorithm, and whiteboard videos on PPI deprescribing.
• Patients will be followed up for 6 months to monitor changes in PPI use, symptoms, and quality of life.

Full description

The RAK-PRIDE Study aims to evaluate the impact of a pharmacist-led educational intervention on the inappropriate use of proton pump inhibitors (PPIs) among adult patients in Ras Al Khaimah. This intervention will focus on both patient education and physician guidance, promoting evidence-based deprescribing practices for PPIs.

Enrollment: 479 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Physicians will be eligible to participate if:

• They are prescribing PPIs in outpatient department of the study sites
• They have patients with potentially inappropriate PPI prescriptions

Patients will be eligible to participate if:

• They are ≥18 years
• They are presenting to out-patient departments of the study sites
• They have prescriptions of potentially inappropriate PPIs
• Their treating physicians are included in the study

Exclusion criteria

Physicians will be excluded if:

• They are involved in any other prescribing trial

Patients will be excluded if:

• They are unable to give informed consent, as judged by their physicians
• They have definitive indications for PPI use

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

479 participants in 2 patient groups

Pharmacist-Led Educational Intervention

Experimental group

Description:

Physicians and patients in this arm will receive a multi-faceted pharmacist-led educational intervention. This includes evidence-based deprescribing guidelines, brochures, videos, and decision aids to promote appropriate use of PPIs and reduce unnecessary prescriptions. The intervention is delivered in four parts: educational brochures, deprescribing algorithm, patient action plans, and video-based education sessions.

Treatment:

Other: Pharmacist-Led Educational Intervention

Control

Other group

Description:

Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions.

Treatment:

Other: Control (Standard treatment)